ArticleClinical and experimental medicine2025
Serum uric acid to high‑density lipoprotein cholesterol ratio as a novel predictor of diabetic nephropathy: a cross‑sectional analysis of NHANES 2011-2018.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
By 2045, 783 million people are predicted to suffer from diabetes, a common metabolic disease. The development of diabetic nephropathy (DN), one of its most dangerous side effects, can lead to end-stage kidney disease. One new biomarker that has been connected to metabolic and inflammatory processes is the Uric Acid/High-Density Lipoprotein Cholesterol Ratio (UHR), which may be useful in DN prediction. Approaches In this study, 17,227 people' data from the NHANES database (2011-2018) were examined. HDL cholesterol levels were divided by serum uric acid levels to calculate UHR. If the albumin-to-creatinine ratio (ACR) was 30 µg/mg or above, it was considered DN. Numerous clinical and demographic factors were used in the analysis. Decision curve analysis, univariate logistic regression, and ROC curves were used to investigate the relationship between UHR and DN. DN risk were positively correlated with UHR (OR 1.19, 95% CI 1.17-1.22, P < 0.0001). The AUC for UHR was 0.617, according to the ROC curve study. There was a 44% increased risk of DN for every unit rise in UHR (OR 1.44, 95% CI 1.23-1.69). A 14% increase in the likelihood of DN was noted for UHR levels over 5.44, indicating a substantial linear association between UHR and DN risk. Higher UHR quartiles translate into more risk, so UHR is a major predictor of DN. The possible clinical use of UHR for DN risk assessment is emphasized in this work.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.